Tevimbra 10mg/ml injection 1vial x 10ml(tislelizumab-jsgr)

Reference priceINR ₹52,500.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.

Brand	Tevimbra
Manufacturer	BeiGene Germany GmbH
Prescription required	Yes

Description

Tevimbra 10mg/ml injection 1vial x 10ml(tislelizumab-jsgr) is a medicine catalog record in the MediPriceHub database. Active ingredient: tislelizumab-jsgr. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: BeiGene Germany GmbH. Therapeutic category: Medicine Library > Oncology Medicines > Esophageal carcinoma (squamous cell carcinoma of the esophagus. Pack information: 100 / 10 (10 / ). Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.

Benefits

TEVIMBRA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for: Esophageal Cancer Gastric Cancer Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1). as a single agent in adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. in combination with platinum and fluoropyrimidine-based chemotherapy in adults for the first line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (≥1). in combination with zanidatamab-hrii and fluoropyrimidine- and platinum-containing chemotherapy in adults for the first line treatment of HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.

How to Use

Use tislelizumab-jsgr under the supervision of a qualified healthcare professional. It should be prepared and administered only by trained healthcare professionals in a setting appropriate for injectable or infusion medicines. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.

Specification

Active ingredient: tislelizumab-jsgr. Pack size: 100 / 10 (10 / ). Pack unit: bottle. Manufacturer: BeiGene Germany GmbH. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Esophageal carcinoma (squamous cell carcinoma of the esophagus. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.

Side Effects

The available source record does not provide a clean, product-specific adverse-reaction list. Potential risks depend on the active ingredient, dose, route, treatment duration, and patient condition. Check the approved local prescribing information for the complete adverse-reaction profile, warnings, contraindications, and monitoring requirements. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, serious bleeding, or rapidly worsening symptoms.

यह जानकारी केवल संदर्भ के लिए है। किसी भी दवा का उपयोग करने से पहले स्वास्थ्य विशेषज्ञ से सलाह लें।